Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538318 | 0.94 | HDAC4 (0.43) | CYP3A4GPBAR1HDAC4MEN1KMT2A | |
| SCHEMBL23531675 | 0.94 | HDAC4 (0.43) | CYP3A4GPBAR1HDAC4MEN1KMT2A | |
| SCHEMBL29972688 | 0.94 | HDAC4 (0.43) | CYP3A4GPBAR1HDAC4MEN1KMT2A | |
| Laquinimod SCHEMBL29438575 | 0.92 | TP53 (0.50) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| Laquinimod SCHEMBL39440 | 0.92 | TP53 (0.50) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| Laquinimod SCHEMBL1573702 | 0.91 | TP53 (0.49) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| Laquinimod SCHEMBL1573491 | 0.91 | TP53 (0.49) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| Laquinimod SCHEMBL1573704 | 0.91 | TP53 (0.49) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| Laquinimod SCHEMBL1573337 | 0.91 | TP53 (0.49) | GPBAR1HDAC4MEN1KMT2ATP53 | |
| SCHEMBL7537716 | 0.90 | HDAC4 (0.43) | CYP3A4GPBAR1HDAC4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | CYP4F3, IRF3, CXCR3 | CYP3A4 131/4885GPBAR1 616/4885HDAC4 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.